文献速递治疗药物监测与药物基因组学特殊人群用药药物不良反应与药物警戒

老年患者利奈唑胺谷浓度超治疗范围:呼吁行动?

Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action?
PubMed 文献 · Clin Pharmacokinet · 2020-11-12

该研究回顾了2016至2020年间3250次利奈唑胺治疗药物监测请求,发现谷浓度随年龄增长显著升高,每增加10岁浓度约升高30%。超过80岁患者中约65%在首次监测时谷浓度超治疗范围,提示常规剂量可能使老年人药物暴露过高,增加血液学毒性风险。

要点

  • 利奈唑胺谷浓度随年龄递增,每增加10岁约上升30%。
  • 超过80岁患者中约65%首次监测谷浓度超治疗范围(>8 mg/L)。
  • 老年患者常规600mg每日两次给药可能暴露过高,建议考虑减量并借助TDM。

核心结论

  • 老年患者接受常规剂量利奈唑胺可能面临药物暴露过高风险,进而增加药物相关血液学毒性。
  • 建议在治疗失败风险低的老年患者中考虑减量方案,并以治疗药物监测指导。

研究设计与样本

  • 回顾性分析2016年1月至2020年6月间收集的3250次利奈唑胺治疗药物监测请求。
  • 将谷浓度作为连续变量和分类变量(<2、2-8、>8 mg/L),按年龄和性别分层比较。

主要发现

  • 利奈唑胺谷浓度从<50岁患者的5.8±5.6 mg/L升高至>90岁患者的16.6±10.0 mg/L。
  • 每增加10岁,谷浓度总体升高30%。
  • 首次监测时,<65岁、65-80岁和>80岁患者中分别有近30%、50%和65%谷浓度超治疗范围。
  • 2016年至2020年间上述趋势无显著变化。

关键数值与推荐

  • 文献提出的治疗范围:<2、2-8和>8 mg/L。

临床怎么用

  • 对老年患者使用利奈唑胺时应警惕谷浓度过高,考虑减少剂量。
  • 建议在低治疗失败风险的老年患者中开展治疗药物监测以指导个体化给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: According to the drug label, linezolid dosage adjustments are not needed in geriatric patients. Nevertheless, clinical evidence suggests that elderly patients may benefit from the use of reduced linezolid doses to limit drug overexposure. Here, we aimed to describe the results of the last 5 years of therapeutic drug monitoring of linezolid in our institution with a special focus on elderly patients. METHODS: Linezolid therapeutic drug monitoring requests collected between January 2016 and June 2020 were considered. Linezolid trough concentrations were considered both as a continuous variable and as a categorical variable, clustering data according to the therapeutic range proposed by available literature (< 2, 2-8, and > 8 mg/L, respectively). Patients' age and sex were considered as categorical variables. Comparisons of linezolid trough concentrations between groups of patients stratified according to age were performed using an analysis of variance; comparisons in the frequency distributions were performed using the chi-squared test. RESULTS: From 2016 to 2020, we collected 3250 linezolid TDM requests. A highly significant, progressive increment in the linezolid trough concentrations was observed moving from patients aged < 50 years (5.8 ± 5.6 mg/L) to those aged > 90 years (16.6 ± 10.0 mg/L), with an overall increment of 30% per decade of age. Nearly 30%, 50%, and 65% of patients aged < 65 years, 65-80 years, and > 80 years, respectively, had supra-therapeutic linezolid trough concentrations at the first therapeutic drug monitoring assessment. This trend did not change significantly moving from 2016 to 2020. CONCLUSIONS: Elderly patients given linezolid at the conventional 600-mg twice-daily dose might be at a high risk of being overexposed to treatment, eventually increasing their risk to experience drug-related hematological toxicity. Reduced linezolid dosing schemes should be potentially considered in elderly patients at a low risk of treatment failure, ideally guided by therapeutic drug monitoring.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Cattaneo D, Fusi M, Cozzi V, et al. Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action? Clin Pharmacokinet. 2020. PMID: 33180272. doi:10.1007/s40262-020-00964-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。